2019
DOI: 10.7150/jca.30323
|View full text |Cite
|
Sign up to set email alerts
|

Co-delivery of Cyclopamine and Doxorubicin Mediated by Bovine Serum Albumin Nanoparticles Reverses Doxorubicin Resistance in Breast Cancer by Down-regulating P-glycoprotein Expression

Abstract: Combination chemotherapy is considered to be one of the most effective treatments for breast cancer by reducing the emergence of drug resistance. In this study, a novel drug delivery system based on bovine serum albumin nanoparticles (BSA NPs) was successfully developed. Doxorubicin (DOX) and cyclopamine (CYC), a potential anti-cancer agent that inhibits the hedgehog signaling pathway were entrapped into BSA NPs through electrostatic interactions and hydrophobic interactions, respectively. Rather than simple c… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
13
0

Year Published

2020
2020
2022
2022

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 37 publications
(13 citation statements)
references
References 45 publications
0
13
0
Order By: Relevance
“…The mixture was magnetically stirred at 750 rpm in a 65 °C water bath. Then, the colloidal solution was ultra-filtered to remove any excess buffer or drug [41] . Figure 2.…”
Section: Thermal-induced Aggregationmentioning
confidence: 99%
“…The mixture was magnetically stirred at 750 rpm in a 65 °C water bath. Then, the colloidal solution was ultra-filtered to remove any excess buffer or drug [41] . Figure 2.…”
Section: Thermal-induced Aggregationmentioning
confidence: 99%
“…As a result, any doxorubicin taken up by the cancer cells would be moved out [81]. Another DDS based on bovine serum albumin nanoparticles for codelivery of doxorubicin and cyclopamine was developed by Lu et al Similar to curcumin, cyclopamine can increase doxorubicin accumulation by inhibiting P-glycoprotein expression [84,85]. Antitumor activity of the formulation was evaluated in doxorubicin-resistant breast cancer cells (MDA-MB-231 cells) and tumor-bearing mice.…”
Section: Dextran-based Nanoparticles For Cancer Therapymentioning
confidence: 99%
“…The nanoformulation significantly reversed the drug resistance in the cancer cell model. It could distribute at the tumor sites and metastatic lymph nodes in the xenograft model, inhibiting tumor growth and reducing distant metastasis [84]. Human serum albumin was also employed for the development of nanoparticle-based DDSs.…”
Section: Dextran-based Nanoparticles For Cancer Therapymentioning
confidence: 99%
See 1 more Smart Citation
“…To overcome the problem of acquired resistance to doxorubicin [55] due to increased extrusion by the ATP-binding cassette (ABC) proteins, doxorubicin was conjugated with bovine serum albumin (BSA) NPs in association with cyclopamine, an inhibitor of the hedgehog pathway, which decreases the expression of ABC proteins. This approach led to the intracellular accumulation of doxorubicin and restored the sensitivity of breast cancer cells to doxorubicin [56]. In a recent work, Yang and colleagues [57] used mesoporous silica NPs (MSNPs), which are internalized by endocytosis, to target a human acute lymphoblastic leukemia (ALL) cell line.…”
Section: Use Of Nanoparticles For Redox-controlled Drug Deliverymentioning
confidence: 99%